These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16239392)

  • 1. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis.
    Roberts L; McColl GJ
    Intern Med J; 2004 Dec; 34(12):687-93. PubMed ID: 15610214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-rheumatoid biologics and pharmacoeconomic evaluation].
    Tsutani K; Igarashi A
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():711-8. PubMed ID: 15799447
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.
    Kirchhoff T; Ruof J; Mittendorf T; Rihl M; Bernateck M; Mau W; Zeidler H; Schmidt RE; Merkesdal S
    Rheumatology (Oxford); 2011 Apr; 50(4):756-61. PubMed ID: 21149243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
    McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
    J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical and economic aspects of rheumatoid arthritis].
    Fautrel B; Gaujoux-Viala C
    Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
    Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
    Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis?
    March L; Lapsley H
    Best Pract Res Clin Rheumatol; 2001 Mar; 15(1):171-85. PubMed ID: 11358421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic consequences of established rheumatoid arthritis and its treatment.
    Kavanaugh A
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):929-42. PubMed ID: 17870036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database.
    Staples MP; March L; Lassere M; Reid C; Buchbinder R
    Rheumatology (Oxford); 2011 Jan; 50(1):166-75. PubMed ID: 20929971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors for rheumatoid arthritis.
    Kamal KM; Miller LA; Kavookjian J; Madhavan S
    Semin Arthritis Rheum; 2006 Aug; 36(1):50-60. PubMed ID: 16887468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies.
    Lipsky PE; Kavanaugh A
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():41-4. PubMed ID: 10646490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.